ACOG Practice Bulletin No. 204: Fetal Growth Restriction

Obstetrics and Gynecology

Volumn 133, Issue 2, 2019, Pages E297-E109

  Galan, Henry ^a   Grobman, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TERATOGENIC AGENT;

BIRTH WEIGHT; CONGENITAL MALFORMATION; DIAGNOSTIC PROCEDURE; DISEASE SURVEILLANCE; DOPPLER FLOWMETRY; FETUS; FETUS ECHOGRAPHY; FETUS GROWTH; FETUS WEIGHT; GENETIC COUNSELING; GENETIC DISORDER; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; INTRAUTERINE INFECTION; MATERNAL DISEASE; MATERNAL NUTRITION; MEDICAL HISTORY; MEDICAL TERMINOLOGY; MULTIPLE PREGNANCY; OBSTETRIC DELIVERY; PERINATAL MORBIDITY; PERINATAL MORTALITY; PHYSICAL EXAMINATION; PLACENTA DISORDER; PREGNANCY; PRENATAL DIAGNOSIS; PRENATAL EXPOSURE; PRENATAL SCREENING; PREVALENCE; PRIORITY JOURNAL; REVIEW; SMALL FOR DATE INFANT; SUBSTANCE ABUSE; SUBSTANCE USE; UMBILICAL CORD; FEMALE; PRACTICE GUIDELINE;

DELIVERY, OBSTETRIC; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HUMANS; PREGNANCY;

EID: 85060526039     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000003070     Document Type: Review

References (147)

1. Dunn PM. The search for perinatal definitions and standards. Acta Paediatr Scand Suppl 1985;319:7–16. (Level III)
2. World Health Organization. Report of a scientific group on health statistics methodology related to perinatal events. Document ICD/PE/74.4:1. Geneva: WHO; 1974. (Level III)
3. Hoffman HJ, Stark CR, Lundin FE Jr, Ashbrook JD. Analysis of birth weight, gestational age, and fetal viability, U. S. births, 1968. Obstet Gynecol Surv 1974;29:651–81. (Level II-3)
4. Battaglia FC, Lubchenco LO. A practical classification of newborn infants by weight and gestational age. J Pediatr 1967;71:159–63. (Level III)
5. Beckmann CR, Ling FW, Barzansky BM, Herbert WN, Laube DW, Smith RP. Obstetrics and gynecology. 6th ed. Baltimore (MD): Lippincott Williams & Wilkins; 2010. (Level III)
6. Galan HL. Timing delivery of the growth-restricted fetus. Semin Perinatol 2011;35:262–9. (Level III)
7. Platz E, Newman R. Diagnosis of IUGR: traditional biometry. Semin Perinatol 2008;32:140–7. (Level III)
8. Xu H, Simonet F, Luo ZC. Optimal birth weight percentile cut-offs in defining small- or large-for-gestational-age. Acta Paediatr 2010;99:550–5. (Level II-3)
9. Ananth CV, Vintzileos AM. Distinguishing pathological from constitutional small for gestational age births in population-based studies. Early Hum Dev 2009;85:653–8. (Level II-3)
10. Bukowski R, Uchida T, Smith GC, Malone FD, Ball RH, Nyberg DA, et al. Individualized norms of optimal fetal growth: fetal growth potential. First and Second Trimester Evaluation of Risk (FASTER) Research Consortium. Obstet Gynecol 2008;111:1065–76. (Level II-2)
11. Gardosi J, Mul T, Mongelli M, Fagan D. Analysis of birthweight and gestational age in antepartum stillbirths. Br J Obstet Gynaecol 1998;105:524–30. (Level III)
12. Ounsted M, Moar VA, Scott A. Risk factors associated with small-for-dates and large-for-dates infants. Br J Obstet Gynaecol 1985;92:226–32. (Level II-3)
13. Cunningham FG, Cox SM, Harstad TW, Mason RA, Pritchard JA. Chronic renal disease and pregnancy outcome. Am J Obstet Gynecol 1990;163:453–9. (Level III)
14. Duvekot JJ, Cheriex EC, Pieters FA, Menheere PP, Schouten HJ, Peeters LL. Maternal volume homeostasis in early pregnancy in relation to fetal growth restriction. Obstet Gynecol 1995;85:361–7. (Level III)
15. Antiphospholipid syndrome. Practice Bulletin No. 132. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:1514–21. (Level III)
16. Facco F, You W, Grobman W. Genetic thrombophilias and intrauterine growth restriction: a meta-analysis. Obstet Gynecol 2009;113:1206–16. (Level III)
17. Said JM, Higgins JR, Moses EK, Walker SP, Borg AJ, Monagle PT, et al. Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women. Obstet Gynecol 2010;115:5–13. (Level II-2)
18. Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G Jr, Wenstrom K, et al. Prothrombin gene G20210A mutation and obstetric complications. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units (NICHD MFMU) Network. Obstet Gynecol 2010;115:14–20. (Level II-2)
19. Bada HS, Das A, Bauer CR, Shankaran S, Lester BM, Gard CC, et al. Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure. J Perinatol 2005;25:631–7. (Level II-3)
20. Shu XO, Hatch MC, Mills J, Clemens J, Susser M. Maternal smoking, alcohol drinking, caffeine consumption, and fetal growth: results from a prospective study. Epidemiology 1995;6:115–20. (Level II-2)
21. Mills JL, Graubard BI, Harley EE, Rhoads GG, Berendes HW. Maternal alcohol consumption and birth weight. How much drinking during pregnancy is safe? JAMA 1984;252:1875–9. (Level II-2)
22. Virji SK. The relationship between alcohol consumption during pregnancy and infant birthweight. An epidemiologic study. Acta Obstet Gynecol Scand 1991;70:303–8. (Level II-3)
23. Naeye RL, Blanc W, Leblanc W, Khatamee MA. Fetal complications of maternal heroin addiction: abnormal growth, infections, and episodes of stress. J Pediatr 1973;83:1055–61. (Level III)
24. Fulroth R, Phillips B, Durand DJ. Perinatal outcome of infants exposed to cocaine and/or heroin in utero. Am J Dis Child 1989;143:905–10. (Level II-3)
25. Little BB, Snell LM, Klein VR, Gilstrap LC III. Cocaine abuse during pregnancy: maternal and fetal implications. Obstet Gynecol 1989;73:157–60. (Level II-3)
26. Antonov AN. Children born during the siege of Leningrad in 1942. J Pediatr 1947;30:250–9. (Level III)
27. Smith CA. Effects of maternal under nutrition upon the newborn infant in Holland (1944–1945). J Pediatr 1947; 30:229–43. (Level III)
28. Say L, Gulmezoglu AM, Hofmeyr GJ. Maternal nutrient supplementation for suspected impaired fetal growth. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD000148. DOI: 10.1002/14651858. CD000148. (Meta-analysis)
29. Guyer B, MacDorman MF, Martin JA, Peters KD, Strobino DM. Annual summary of vital statistics-1997. Pediatrics 1998;102:1333–49. (Level III)
30. Powers WF, Kiely JL. The risks confronting twins: a national perspective. Am J Obstet Gynecol 1994;170: 456–61. (Level II-3)
31. Houlton MC, Marivate M, Philpott RH. The prediction of fetal growth retardation in twin pregnancy. Br J Obstet Gynaecol 1981;88:264–73. (Level II-3)
32. Mauldin JG, Newman RB. Neurologic morbidity associated with multiple gestation. Female Patient 1998;23(4): 27–46. (Level III)
33. Denbow ML, Cox P, Taylor M, Hammal DM, Fisk NM. Placental angioarchitecture in monochorionic twin pregnancies: relationship to fetal growth, fetofetal transfusion syndrome, and pregnancy outcome. Am J Obstet Gynecol 2000;182:417–26. (Level III)
34. Maulik D. Fetal growth restriction: the etiology. Clin Obstet Gynecol 2006;49:228–35. (Level III)
35. Battino D, Granata T, Binelli S, Caccamo ML, Canevini MP, Canger R, et al. Intrauterine growth in the offspring of epileptic mothers. Acta Neurol Scand 1992;86:555–7. (Level III)
36. Mastroiacovo P, Bertollini R, Licata D. Fetal growth in the offspring of epileptic women: results of an Italian multicentric cohort study. Acta Neurol Scand 1988;78: 110–4. (Level II-2)
37. Aviles A, Diaz-Maqueo JC, Talavera A, Guzman R, Garcia EL. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 1991;36:243–8. (Level III)
38. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122–40. (Level III)
39. Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore TR, editors. Creasy and Resnik’s maternal–fetal medicine: principles and practice. 6th ed. Philadelphia (PA): Saunders Elsevier; 2009. (Level III)
40. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007;7:93–104. (Level III)
41. Donner C, Liesnard C, Content J, Busine A, Aderca J, Rodesch F. Prenatal diagnosis of 52 pregnancies at risk for congenital cytomegalovirus infection. Obstet Gynecol 1993;82:481–6. (Level III)
42. Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team. AIDS 2000;14:1389–99. (Level I)
43. Cailhol J, Jourdain G, Coeur SL, Traisathit P, Boonrod K, Prommas S, et al. Association of low CD4 cell count and intrauterine growth retardation in Thailand. Perinatal HIV Prevention Trial Group. J Acquir Immune Defic Syndr 2009;50:409–13. (Level I)
44. Iqbal SN, Kriebs J, Harman C, Alger L, Kopelman J, Turan O, et al. Predictors of fetal growth in maternal HIV disease. Am J Perinatol 2010;27:517–23. (Level II-3)
45. Eydoux P, Choiset A, Le Porrier N, Thepot F, Szpiro-Tapia S, Alliet J, et al. Chromosomal prenatal diagnosis: study of 936 cases of intrauterine abnormalities after ultrasound assessment. Prenat Diagn 1989;9:255–69. (Level III)
46. Wolstenholme J, Rooney DE, Davison EV. Confined placental mosaicism, IUGR, and adverse pregnancy outcome: a controlled retrospective U.K. collaborative survey. Prenat Diagn 1994;14:345–61. (Level II-2)
47. Wilkins-Haug L, Roberts DJ, Morton CC. Confined placental mosaicism and intrauterine growth retardation: a case-control analysis of placentas at delivery. Am J Obstet Gynecol 1995;172:44–50. (Level III)
48. Khoury MJ, Erickson JD, Cordero JF, McCarthy BJ. Congenital malformations and intrauterine growth retardation: a population study. Pediatrics 1988;82:83–90. (Level II-3)
49. Wallenstein MB, Harper LM, Odibo AO, Roehl KA, Longman RE, Macones GA, et al. Fetal congenital heart disease and intrauterine growth restriction: a retrospective cohort study. J Matern Fetal Neonatal Med 2012;25:662–5. (Level II-3)
50. Malik S, Cleves MA, Zhao W, Correa A, Hobbs CA. Association between congenital heart defects and small for gestational age. National Birth Defects Prevention Study. Pediatrics 2007;119:e976–82. (Level II-3)
51. Raynor BD, Richards D. Growth retardation in fetuses with gastroschisis. J Ultrasound Med 1997;16:13–6. (Level III)
52. Salafia CM, Minior VK, Pezzullo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks’ gestation: associated placental pathologic features. Am J Obstet Gynecol 1995;173:1049–57. (Level II-3)
53. Laurini R, Laurin J, Marsal K. Placental histology and fetal blood flow in intrauterine growth retardation. Acta Obstet Gynecol Scand 1994;73:529–34. (Level III)
54. Shanklin DR. The influence of placental lesions on the newborn infant. Pediatr Clin North Am 1970;17:25–42. (Level II-3)
55. Ananth CV, Demissie K, Smulian JC, Vintzileos AM. Relationship among placenta previa, fetal growth restriction, and preterm delivery: a population-based study. Obstet Gynecol 2001;98:299–306. (Level II-3)
56. Ananth CV, Wilcox AJ. Placental abruption and perinatal mortality in the United States. Am J Epidemiol 2001;153: 332–7. (Level II-3)
57. Chapman MG, Furness ET, Jones WR, Sheat JH. Significance of the ultrasound location of placental site in early pregnancy. Br J Obstet Gynaecol 1979;86:846–8. (Level III)
58. Harper LM, Odibo AO, Macones GA, Crane JP, Cahill AG. Effect of placenta previa on fetal growth. Am J Obstet Gynecol 2010;203:330.e1–e5. (Level II-2)
59. Pollack RN, Divon MY. Intrauterine growth retardation: definition, classification, and etiology. Clin Obstet Gynecol 1992;35:99–107. (Level III)
60. Thummala MR, Raju TN, Langenberg P. Isolated single umbilical artery anomaly and the risk for congenital malformations: a meta-analysis. J Pediatr Surg 1998;33:580–5. (Meta-Analysis)
61. Heifetz SA. Single umbilical artery. A statistical analysis of 237 autopsy cases and review of the literature. Perspect Pediatr Pathol 1984;8:345–78. (Level III)
62. Resnik R. Intrauterine growth restriction. Obstet Gynecol 2002;99:490–6. (Level III)
63. Pallotto EK, Kilbride HW. Perinatal outcome and later implications of intrauterine growth restriction. Clin Obstet Gynecol 2006;49:257–69. (Level III)
64. Barker DJ. Adult consequences of fetal growth restriction. Clin Obstet Gynecol 2006;49:270–83. (Level III)
65. Clausson B, Cnattingius S, Axelsson O. Outcomes of post-term births: the role of fetal growth restriction and malformations. Obstet Gynecol 1999;94:758–62. (Level II-3)
66. Getahun D, Ananth CV, Kinzler WL. Risk factors for antepartum and intrapartum stillbirth: a population-based study. Am J Obstet Gynecol 2007;196:499–507. (Level II-3)
67. Ego A, Subtil D, Grange G, Thiebaugeorges O, Senat MV, Vayssiere C, et al. Customized versus population-based birth weight standards for identifying growth restricted infants: a French multicenter study. Am J Obstet Gynecol 2006;194:1042–9. (Level II-3)
68. Vergani P, Roncaglia N, Locatelli A, Andreotti C, Crippa I, Pezzullo JC, et al. Antenatal predictors of neonatal outcome in fetal growth restriction with absent end-diastolic flow in the umbilical artery. Am J Obstet Gynecol 2005; 193:1213–8. (Level II-3)
69. McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and mortality among newborn infants. N Engl J Med 1999;340:1234–8. (Level II-2)
70. Hartung J, Kalache KD, Heyna C, Heling KS, Kuhlig M, Wauer R, et al. Outcome of 60 neonates who had ARED flow prenatally compared with a matched control group of appropriate-for-gestational age preterm neonates. Ultrasound Obstet Gynecol 2005;25:566–72. (Level II-2)
71. Shand AW, Hornbuckle J, Nathan E, Dickinson JE, French NP. Small for gestational age preterm infants and relationship of abnormal umbilical artery Doppler blood flow to perinatal mortality and neurodevelopmental outcomes. Aust N Z J Obstet Gynaecol 2009;49:52–8. (Level II-2)
72. Jones RA, Roberton NR. Problems of the small-for-dates baby. Clin Obstet Gynaecol 1984;11:499–524. (Level III)
73. Alkalay AL, Graham JM Jr, Pomerance JJ. Evaluation of neonates born with intrauterine growth retardation: review and practice guidelines. J Perinatol 1998;18:142–51. (Level III)
74. Knox AJ, Sadler L, Pattison NS, Mantell CD, Mullins P. An obstetric scoring system: its development and application in obstetric management. Obstet Gynecol 1993;81:195–9. (Level II-3)
75. Leeson S, Aziz N. Customised fetal growth assessment. Br J Obstet Gynaecol 1997;104:648–51. (Level III)
76. Jahn A, Razum O, Berle P. Routine screening for intrauterine growth retardation in Germany: low sensitivity and questionable benefit for diagnosed cases. Acta Obstet Gynecol Scand 1998;77:643–8. (Level II-3)
77. Kean LH, Liu DT. Antenatal care as a screening tool for the detection of small for gestational age babies in the low risk population. J Obstet Gynaecol 1996;16:77–82. (Level II-3)
78. Sparks TN, Cheng YW, McLaughlin B, Esakoff TF, Caughey AB. Fundal height: a useful screening tool for fetal growth? J Matern Fetal Neonatal Med 2011;24:708–12. (Level II-2)
79. Goetzinger KR, Tuuli MG, Odibo AO, Roehl KA, Macones GA, Cahill AG. Screening for fetal growth disorders by clinical exam in the era of obesity. J Perinatol 2012; DOI: 10.1038/jp.2012.130; 10.1038/jp.2012.130. (Level II-2)
80. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements––a prospective study. Am J Obstet Gynecol 1985;151:333–7. (Level III)
81. Hadlock FP, Harrist RB, Carpenter RJ, Deter RL, Park SK. Sonographic estimation of fetal weight. The value of femur length in addition to head and abdomen measurements. Radiology 1984;150:535–40. (Level III)
82. Chien PF, Owen P, Khan KS. Validity of ultrasound estimation of fetal weight. Obstet Gynecol 2000;95:856–60. (Level II-2)
83. Dudley NJ. A systematic review of the ultrasound estimation of fetal weight. Ultrasound Obstet Gynecol 2005;25: 80–9. (Level III)
84. Berkley E, Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. Society for Maternal-Fetal Medicine Publications Committee [published erratum appears in Am J Obstet Gynecol 2012;206:508]. Am J Obstet Gynecol 2012;206:300–8. (Level III)
85. Kingdom JC, Burrell SJ, Kaufmann P. Pathology and clinical implications of abnormal umbilical artery Doppler waveforms. Ultrasound Obstet Gynecol 1997;9:271–86. (Level III)
86. Pardi G, Cetin I, Marconi AM, Lanfranchi A, Bozzetti P, Ferrazzi E, et al. Diagnostic value of blood sampling in fetuses with growth retardation. N Engl J Med 1993;328: 692–6. (Level III)
87. Nicolaides KH, Bilardo CM, Soothill PW, Campbell S. Absence of end diastolic frequencies in umbilical artery: a sign of fetal hypoxia and acidosis. BMJ 1988;297:1026–7. (Level III)
88. Bilardo CM, Nicolaides KH, Campbell S. Doppler measurements of fetal and uteroplacental circulations: relationship with umbilical venous blood gases measured at cordocentesis. Am J Obstet Gynecol 1990;162:115–20. (Level III)
89. Giles W, Bisits A. Clinical use of Doppler ultrasound in pregnancy: information from six randomised trials. Fetal Diagn Ther 1993;8:247–55. (Level III)
90. Alfirevic Z, Stampalija T, Gyte GML. Fetal and umbilical Doppler ultrasound in normal pregnancy. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001450. DOI: 10.1002/14651858.CD001450.pub3. (Meta-analysis)
91. Rizzo G, Capponi A, Arduini D, Romanini C. The value of fetal arterial, cardiac and venous flows in predicting pH and blood gases measured in umbilical blood at cordocentesis in growth retarded fetuses. Br J Obstet Gynaecol 1995;102:963–9. (Level III)
92. Hecher K, Snijders R, Campbell S, Nicolaides K. Fetal venous, intracardiac, and arterial blood flow measurements in intrauterine growth retardation: relationship with fetal blood gases. Am J Obstet Gynecol 1995;173:10–5. (Level III)
93. Baschat AA. Doppler application in the delivery timing of the preterm growth-restricted fetus: another step in the right direction. Ultrasound Obstet Gynecol 2004;23: 111–8. (Level III)
94. Ghidini A. Doppler of the ductus venosus in severe preterm fetal growth restriction: a test in search of a purpose? Obstet Gynecol 2007;109:250–2. (Level III)
95. Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC. Role of the IGF system in trophoblast invasion and preeclampsia. Hum Reprod 1999;14(suppl 2):90–6. (Level III)
96. Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2008;31:15–9. (Level II-3)
97. Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Am J Obstet Gynecol 2004;191:1452–8. (Level II-2)
98. Goetzl L, Krantz D, Simpson JL, Silver RK, Zachary JM, Pergament E, et al. Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss. Obstet Gynecol 2004;104:30–6. (Level II-2)
99. Dugoff L. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Society for Maternal-Fetal Medicine. Obstet Gynecol 2010;115:1052–61. (Level II-2)
100. Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010;30: 293–308. (Level III)
101. Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11–13 weeks. Prenat Diagn 2010;30:216–23. (Level II-2)
102. Goetzinger KR, Singla A, Gerkowicz S, Dicke JM, Gray DL, Odibo AO. Predicting the risk of pre-eclampsia between 11 and 13 weeks’ gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta-hCG. Prenat Diagn 2010;30:1138–42. (Level II-3)
103. Morris RK, Malin G, Robson SC, Kleijnen J, Zamora J, Khan KS. Fetal umbilical artery Doppler to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011;37:135–42. (Meta-analysis)
104. Silver RM, Varner MW, Reddy U, Goldenberg R, Pinar H, Conway D, et al. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol 2007;196:433–44. (Level III)
105. Kafatos AG, Vlachonikolis IG, Codrington CA. Nutrition during pregnancy: the effects of an educational intervention program in Greece. Am J Clin Nutr 1989;50:970–9. (Level II-1)
106. Khoury J, Henriksen T, Christophersen B, Tonstad S. Effect of a cholesterol-lowering diet on maternal, cord, and neonatal lipids, and pregnancy outcome: a randomized clinical trial. Am J Obstet Gynecol 2005;193:1292–301. (Level I)
107. Steegers EA, Van Lakwijk HP, Jongsma HW, Fast JH, De Boo T, Eskes TK, et al. (Patho)physiological implications of chronic dietary sodium restriction during pregnancy; a longitudinal prospective randomized study. Br J Obstet Gynaecol 1991;98:980–7. (Level I)
108. Pena-Rosas JP, De-Regil LM, Dowswell T, Viteri FE. Daily oral iron supplementation during pregnancy. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD004736. DOI: 10.1002/14651858. CD004736.pub4. (Level III)
109. Mori R, Ota E, Middleton P, Tobe-Gai R, Mahomed K, Bhutta ZA. Zinc supplementation for improving pregnancy and infant outcome. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD000230. DOI: 10.1002/14651858.CD000230.pub4. (Meta-analysis)
110. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD001059. DOI: 10.1002/14651858.CD001059.pub3. (Meta-analysis)
111. Ota E, Tobe-Gai R, Mori R, Farrar D. Antenatal dietary advice and supplementation to increase energy and protein intake. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD000032. DOI: 10. 1002/14651858.CD000032.pub2. (Meta-analysis)
112. Makrides M, Crowther CA. Magnesium supplementation in pregnancy. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD000937. DOI: 10. 1002/14651858.CD000937. (Meta-analysis)
113. De-Regil LM, Palacios C, Ansary A, Kulier R, Pena-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD008873. DOI: 10. 1002/14651858.CD008873.pub2. (Meta-analysis)
114. Say L, Gulmezoglu AM, Hofmeyr GJ. Bed rest in hospital for suspected impaired fetal growth. Cochrane Database of Systematic Reviews 1996, Issue 1. Art. No.: CD000034. DOI: 10.1002/14651858.CD000034. (Meta-analysis)
115. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116: 402–14. (Meta-analysis)
116. Peleg D, Kennedy CM, Hunter SK. Intrauterine growth restriction: identification and management. Am Fam Physician 1998;58:453–60, 466–7. (Level III)
117. Gulmezolu M, de Onis M, Villar J. Effectiveness of interventions to prevent or treat impaired fetal growth. Obstet Gynecol Surv 1997;52:139–49. (Level III)
118. Leitich H, Egarter C, Husslein P, Kaider A, Schemper M. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. Br J Obstet Gynaecol 1997;104:450–9. (Meta-analysis)
119. Bahado-Singh RO, Lynch L, Deren O, Morroti R, Copel JA, Mahoney MJ, et al. First-trimester growth restriction and fetal aneuploidy: the effect of type of aneuploidy and gestational age. Am J Obstet Gynecol 1997;176:976–80. (Level II-3)
120. Sassoon DA, Castro LC, Davis JL, Hobel CJ. Perinatal outcome in triplet versus twin gestations. Obstet Gynecol 1990;75:817–20. (Level II-2)
121. Alexandr JM, Hammond KR, Steinkampf MP. Multifetal reduction of high-order multiple pregnancy: comparison of obstetrical outcome with nonreduced twin gestations. Fertil Steril 1995;64:1201–3. (Level III)
122. Silver R, Helfand BT, Russell TL, Ragin A, Sholl JS, MacGregor SN. Multifetal reduction increases the risk of preterm delivery and fetal growth restriction in twins: a case-control study. Fertil Steril 1997;67:30–3. (Level II-2)
123. Multiplegestation: complicated twin, triplet, and high-order multifetal pregnancy. ACOG Practice Bulletin No. 56. American College of Obstetricians and Gynecologists. Obstet Gynecol 2004;104:869–83. (Level III)
124. Machin A. Velamentous cord insertion in monochorionic twin gestation. An added risk factor. J Reprod Med 1997; 42:785–9. (Level III)
125. Divon MY, Chamberlain PF, Sipos L, Manning FA, Platt LD. Identification of the small for gestational age fetus with the use of gestational age-independent indices of fetal growth. Am J Obstet Gynecol 1986;155:1197–201. (Level II-3)
126. Mongelli M, Ek S, Tambyrajia R. Screening for fetal growth restriction: a mathematical model of the effect of time interval and ultrasound error. Obstet Gynecol 1998; 92:908–12. (Level II-3)
127. Arabin B, Bergmann PL, Saling E. Simultaneous assessment of blood flow velocity waveforms in uteroplacental vessels, the umbilical artery, the fetal aorta and the fetal common carotid artery. Fetal Ther 1987; 2:17–26. (Level III)
128. Lees CC, Marlow N, van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. TRUFFLE study group [published erratum appears in Lancet 2015;385:2152]. Lancet 2015;385:2162–72. (Level I)
129. Veille JC, Kanaan C. Duplex Doppler ultrasonographic evaluation of the fetal renal artery in normal and abnormal fetuses. Am J Obstet Gynecol 1989;161:1502–7. (Level III)
130. Gramellini D, Folli MC, Raboni S, Vadora E, Merialdi A. Cerebral-umbilical Doppler ratio as a predictor of adverse perinatal outcome. Obstet Gynecol 1992;79:416–20. (Level III)
131. BahadoSingh RO, Kovanci E, Jeffres A, Oz U, Deren O, Copel J, et al. The Doppler cerebroplacental ratio and perinatal outcome in intrauterine growth restriction. Am J Obstet Gynecol 1999;180:750–6. (Level II-3)
132. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. GRIT Study Group. BJOG 2003;110:27–32. (Level I)
133. Thornton JG, Hornbuckle J, Vail A, Spiegelhalter DJ, Levene M. Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. GRIT study group. Lancet 2004;364:513–20. (Level I)
134. Walker DM, Marlow N, Upstone L, Gross H, Hornbuckle J, Vail A, et al. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol 2011;204:34.e1–e9. (Level I)
135. Boers KE, Vijgen SM, Bijlenga D, van der Post JA, Bekedam DJ, Kwee A, et al. Induction versus expectant monitoring for intrauterine growth restriction at term: randomised equivalence trial (DIGITAT). DIGITAT Study Group. BMJ 2010;341:c7087. (Level I)
136. Spong CY, Mercer BM, D’Alton M, Kilpatrick S, Blackwell S, Saade G. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011;118:323–33. (Level III)
137. Medically indicated late-preterm and early-term deliveries. ACOG Committee Opinion No. 764. American College of Obstetricians and Gynecologists. Obstet Gynecol 2019;133:151–55. (Level III)
138. Berkley E, Chauhan SP, Abuhamad A. Doppler assessment of the fetus with intrauterine growth restriction. Society for Maternal-Fetal Medicine Publications Committee [published errata appear in Am J Obstet Gynecol 2015;212:246; Am J Obstet Gynecol 2012;206:508]. Am J Obstet Gynecol 2012;206:300–8. (Level III)
139. Antenatal corticosteroids revisited: repeat courses. NIH Consens Statement 2000;17:1–18. (Level III)
140. Roberts D, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD004454. DOI: 10. 1002/14651858.CD004454.pub2. (Meta-analysis)
141. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994;12:1–24. (Level III)
142. Gyamfi-Bannerman C, Thom EA, Blackwell SC, Tita AT, Reddy UM, Saade GR, et al. Antenatal betamethasone for women at risk for late preterm delivery. NICHD Maternal-Fetal Medicine Units Network. N Engl J Med 2016;374:1311–20. (Level I)
143. Antenatal corticosteroid therapy for fetal maturation. Committee Opinion No. 713. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130: e102–9. (Level III)
144. Crowther CA, Verkuyl DA, Neilson JP, Bannerman C, Ashurst HM. The effects of hospitalization for rest on fetal growth, neonatal morbidity and length of gestation in twin pregnancy. Br J Obstet Gynaecol 1990;97:872–7. (Level I)
145. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Leveque C, Hellot MF, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*. PREMAG Trial Group. BJOG 2007;114:310–8. (Level I)
146. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. Eunice Kennedy Shriver NICHD Maternal–Fetal Medicine Units Network. N Engl J Med 2008;359:895–905. (Level I)
147. Magnesium sulfate before anticipated preterm birth for neuroprotection. Committee Opinion No. 455. American College of Obstetricians and Gynecologists. Obstet Gynecol 2010;115:669–71. (Level III)